Group 1 - The core viewpoint of the news is that Lanwei Medical has experienced fluctuations in its stock performance and financial metrics, indicating potential investment opportunities and risks in the medical diagnostics sector [1][2]. Group 2 - As of January 29, Lanwei Medical's stock price decreased by 0.52%, with a trading volume of 148 million yuan. The financing buy-in amount was 19.1552 million yuan, while the financing repayment was 13.7929 million yuan, resulting in a net financing buy-in of 5.3622 million yuan. The total financing and securities balance reached 122 million yuan [1]. - The financing balance of Lanwei Medical is 121 million yuan, accounting for 2.65% of its market capitalization, which is above the 90th percentile level over the past year, indicating a high level of financing activity [1]. - On the short-selling side, there were no shares repaid or sold on January 29, with a short-selling balance of 39.79 million yuan, also exceeding the 90th percentile level over the past year [1]. - As of September 30, the number of shareholders for Lanwei Medical was 21,700, a decrease of 6.26% from the previous period, while the average circulating shares per person increased by 6.68% to 16,564 shares [2]. - For the period from January to September 2025, Lanwei Medical reported a revenue of 1.102 billion yuan, a year-on-year decrease of 16.51%. However, the net profit attributable to the parent company was -667,700 yuan, showing a significant year-on-year growth of 98.35% [2]. - Since its A-share listing, Lanwei Medical has distributed a total of 320 million yuan in dividends, with 200 million yuan distributed over the past three years [3].

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 重要内容提示 ： 1、本期业绩预告的具体适用情形：净利润为负值。 2、广州金域医学检验集团股份有限公司（以下简称"公司"）预计2025年 年度实现归属于上 市 公 司 股 东 的 净 利 润 为 -13,000 万 元 到 -19,000 万 元 ， 与 上 年 同 期 相 比 ， 将 同 比 减 亏 19,124.11万元到25,124.11万元。 3、公司预计2025年年度实现归属于上市公司股东的扣除非经常性损益的净 利润为-12,000 万元到-18,000万元。 一、本期业绩预告情况 （一）业绩预告期间 2025 年1月1日至2025年12月31日。 （二）基本每股收益：-0.82元。 三、本期业绩预亏的主要原因 报告期内公司业绩发生变动的主要原因如下： （1）大额减值计提：受宏观环境变化及相关业务周期性影响，部分业务应 收账款账龄延长。 根据会计准则要求，公司依据账龄法已对相关应收账款进行信 用减值计提，经财务部门初步测 算，2025年度公司拟计提信用减值损失约 35,000-39 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2026年1月21日 (二)股东会召开的地点：广州市国际生物岛螺旋三路10号金域医学总部大楼 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次会议由董事会召集，公司董事长梁耀铭先生主持，本次会议的召集、召开及表决形式均符合《公司 法》及《公司章程》的规定。 (五)公司董事和董事会秘书的列席情况 1、公司在任董事9人，列席9人； ■ 2、议案名称：关于变更经营范围暨修订《公司章程》的议案 审议结果：通过 2、董事会秘书汪令来先生出席本次会议；公司全体高管列席本次会议。 二、议案审议情况 (一)非累积投票议案 1、议案名称：广州金域医学检验集团股份有限公司2025年前三季度利润分配预案 审议结果：通过 表决情况： 表决情况： ■ (二)涉及重大事项，5%以下股东的表决情况 ■ (三)关于议案 ...

Group 1 - The core viewpoint of the news is that Lanwei Medical has experienced a decline in stock performance and financial metrics, with significant changes in financing activities and revenue generation [1][2]. Group 2 - On December 23, Lanwei Medical's stock fell by 0.73%, with a trading volume of 44.22 million yuan. The financing buy-in amount was 3.41 million yuan, while the financing repayment was 4.78 million yuan, resulting in a net financing buy of -1.38 million yuan [1]. - As of December 23, the total balance of margin trading for Lanwei Medical was 94.89 million yuan, with the financing balance accounting for 2.48% of the circulating market value, indicating a high level compared to the past year [1]. - The company had no shares sold short on December 23, with a short balance of 3,800 shares valued at 36,300 yuan, also reflecting a high level compared to the past year [1]. - As of September 30, the number of shareholders for Lanwei Medical was 21,700, a decrease of 6.26% from the previous period, while the average circulating shares per person increased by 6.68% to 16,564 shares [2]. - For the period from January to September 2025, Lanwei Medical reported operating revenue of 1.102 billion yuan, a year-on-year decrease of 16.51%, and a net profit attributable to shareholders of -667,700 yuan, which represents a year-on-year increase of 98.35% [2]. - Since its A-share listing, Lanwei Medical has distributed a total of 320 million yuan in dividends, with 200 million yuan distributed over the past three years [3].

Core Viewpoint - The company, Guangzhou Kingmed Medical Laboratory Group Co., Ltd., is set to hold a Q3 2025 earnings briefing on November 20, 2025, to discuss its operational results and financial status with investors [2][3]. Group 1: Meeting Details - The earnings briefing will take place on November 20, 2025, from 15:00 to 16:00 [4]. - The meeting will be conducted online via the Value Online platform [4]. - Investors can participate in the interactive session and submit questions beforehand through a specified website or via email [5]. Group 2: Participation Information - Investors can join the interactive session on November 20, 2025, through the provided URL [5]. - Questions can be submitted until noon on November 19, 2025, either through the website or via email to the company's securities affairs department [5]. Group 3: Contact Information - The securities affairs department can be contacted at the phone number 020-29196326 [6]. - An email address for inquiries is provided: sid@kingmed.com.cn [7].

Core Viewpoint - The company, Kingmed Diagnostics (金域医学), reported a mixed performance in its Q3 2025 financial results, showing a decline in revenue but a significant improvement in net profit, indicating a gradual recovery in profitability despite industry challenges [1] Financial Performance - Q3 2025 revenue was 1.541 billion yuan, a year-on-year decrease of 11.32% - Net profit attributable to shareholders was 5.2 million yuan, a year-on-year increase of 24.08% - Non-recurring net profit attributable to shareholders was 14 million yuan, a year-on-year increase of 264.54% - For the first three quarters, the net profit attributable to shareholders was -80 million yuan, primarily due to a historical credit impairment loss of 345 million yuan [1] Cash Flow and Efficiency - The company's operating net cash flow showed a quarterly increase: 55 million yuan in Q1, 296 million yuan in Q2, and 321 million yuan in Q3, totaling 672 million yuan for the first three quarters - There was a notable improvement in accounts receivable collection [1] Strategic Initiatives - The company is focused on cost reduction, efficiency enhancement, and digital transformation, leading to a gradual increase in gross margin over the first three quarters - Kingmed Diagnostics emphasizes long-termism and innovation, implementing five strategic initiatives: upgrading marketing models, product mix strategies, differentiated services, cost leadership, and digital transformation [1] Market Development - The company has signed 21 community medical projects and won 14 new precision construction projects across various fields, including infection, oncology, genetics, and mass spectrometry - The revenue from the welfare system projects increased by 53.8% year-on-year [2] AI and Technology Integration - Kingmed Diagnostics has initiated the "AI IN ALL" program, advancing its smart medical testing capabilities - The company’s AI model, "Xiao Yu Yi," has been deployed in clinical settings, achieving over 5.99 million calls for smart report interpretations and 140,000 monthly active users [2] Data Trading and Collaboration - The company is the only medical institution selected as a pilot for the national trusted data space innovation development - It has registered six specialized disease datasets and listed 21 data products across various data exchanges, establishing long-term cooperation agreements with multiple stakeholders, including pharmaceutical companies and hospitals [3]

Group 1: Current Development Trends - The company has gradually cleared goodwill and interference from COVID-19 related reports, laying a foundation for future growth [1] - The industry is accelerating the exit of "small and scattered" enterprises, entering a critical period for leading companies [1] - Despite pressures from policies like DRG and centralized procurement, the company is transforming its organizational, business, and product structures [1] Group 2: Five-Year Strategic Plan and Progress - The company aims to enhance internal management and focus on high-quality development, achieving over 25% reduction in procurement costs and 16% and 29% decreases in management and financial expenses respectively [2] - Core technology competitiveness in blood, neuroimmunology, and pathology has been strengthened, with pathogen tNGS, liquid biopsy, and tumor companion diagnostics growing by 35%, 22%, and 20% respectively [2] - The proportion of special testing revenue in diagnostic service revenue has increased to 47.63%, up by 7.32 percentage points from the end of 2024 [2] Group 3: Customer and Market Expansion - The company signed 1,036 new clients in the first half of 2025, with 133 being tertiary hospitals, increasing the revenue share from tertiary hospitals to 49.28% [2] - Cumulative cooperative clients exceed 800, with nearly 100 precision centers established [2] - The company is actively exploring international markets, with Vietnam's lab receiving ISO 15189 certification [2] Group 4: Financial Performance and Cash Flow - Accounts receivable reached 5.383 billion yuan, with a provision of 215 million yuan, indicating an expected improvement in cash flow management [4] - Operating cash flow improved to 278 million yuan, a 199.56% increase compared to the same period in 2024 [4] Group 5: Service and Product Innovations - The company has launched a digital product matrix including data, AI+CDSS, AI+health management, and AI+CRO, with revenue from digital products surpassing the total for the previous year [9] - The gross profit margin for services increased by 0.8 percentage points to 33.12%, attributed to strategic adjustments and optimization of customer structure [10] Group 6: Industry Challenges and Responses - The impact of the Jiangsu province tumor gene testing centralized procurement policy is expected to lower prices significantly, but the company anticipates long-term growth due to its integrated advantages [11] - The company is transitioning from traditional hospital collaborations to a networked service system, enhancing service offerings from diagnosis to full lifecycle management [12] Group 7: Data Utilization and Future Plans - The company has accumulated over 20 PB of data, with annual increments of approximately 1.5 PB, which will be utilized for AI model training and clinical decision support [14] - Future plans include expanding data services and operational management through clinical specialty databases and intelligent inspection platforms [14]

Group 1 - The company plans to abolish the supervisory board and transfer its responsibilities to the audit committee of the board of directors in accordance with the newly revised Company Law of the People's Republic of China [1][2][3] - The company aims to revise its Articles of Association and related rules to enhance corporate governance and comply with the latest regulations from the Shanghai Stock Exchange and other relevant laws [2][3][4] Group 2 - The specific amendments to the Articles of Association include changes to the rights and obligations of shareholders, the structure of the board, and the procedures for shareholder meetings [4][5][6] - The company’s total share capital is stated to be 463.258275 million shares, all of which are ordinary shares [5][6] - The company will not provide financial assistance for others to acquire its shares, except for employee stock ownership plans [6][7]

Core Viewpoint - The document outlines the working guidelines for the Board Secretary of Guangzhou Kingmed Diagnostics Group Co., Ltd, emphasizing the importance of compliance, responsibilities, and qualifications for the role to enhance corporate governance and information disclosure quality [2][4]. Group 1: General Provisions - The guidelines aim to promote standardized operations within the company and enhance the role of the Board Secretary [2]. - The Board Secretary is a senior management position responsible to the Board of Directors [2]. - The Board Secretary must adhere to laws, regulations, and the company's articles of association, bearing fiduciary and diligence obligations [2]. Group 2: Qualifications of the Board Secretary - The Board Secretary must possess at least a college degree and have over three years of experience in relevant fields [5]. - Required knowledge includes finance, taxation, law, finance, corporate management, and computer applications [5]. - A good personal character and professional ethics are essential, along with strong communication skills [5]. Group 3: Responsibilities of the Board Secretary - The Board Secretary is responsible for communication with regulatory bodies and ensuring compliance with reporting obligations [6]. - Duties include managing information disclosure, coordinating board meetings, and maintaining confidentiality of insider information [6][7]. - The role involves managing investor relations and ensuring effective communication with stakeholders [6][7]. Group 4: Appointment and Dismissal of the Board Secretary - The company must appoint a Board Secretary within three months of its initial public offering or the previous Secretary's departure [8]. - The Board Secretary cannot hold other positions in the controlling shareholder's unit, and independent directors cannot serve as Board Secretaries [8]. - Dismissal of the Board Secretary requires valid reasons, and the company must report such actions to regulatory bodies [8]. Group 5: Obligations and Support for the Board Secretary - The Board Secretary must act in the best interest of the company and shareholders, avoiding conflicts of interest [10]. - The company is required to provide necessary support and resources for the Board Secretary to fulfill their duties effectively [12]. - A dedicated securities affairs management department should be established to assist the Board Secretary [12]. Group 6: Accountability System for the Board Secretary - If the Board Secretary sells company shares within six months of purchase, the profits must be returned to the company [15]. - The Board Secretary and responsible personnel are liable for any misleading disclosures that result in investor losses [15]. - The company must cooperate with regulatory investigations if the Board Secretary violates laws or regulations [15].

General Principles - The investment management system aims to standardize the external investment behavior of Guangzhou Kingmed Diagnostics Group Co., Ltd., enhance management, mitigate risks, and protect the interests of investors [1] - External investment refers to the company's various forms of investment activities using monetary funds, equity, or assessed physical or intangible assets for future returns [1] Types of Investments - Investments are categorized into short-term and long-term based on duration, with short-term investments being those that can be liquidated within one year, and long-term investments exceeding one year [1] Investment Approval Authority - The company implements a professional management and hierarchical approval system for external investments, with specific thresholds for approval by the shareholders' meeting, board of directors, and general manager [2][4] - Shareholders' meeting approval is required for transactions exceeding 50% of total assets or net assets, or absolute amounts over 50 million yuan [2] - The board of directors can approve transactions exceeding 10% of total assets or net assets, or absolute amounts over 1 million yuan [2] Investment Management Organization - The shareholders' meeting and board of directors serve as decision-making bodies for external investments, while the general manager is responsible for implementing investment projects [8][9] - The finance department manages daily financial operations related to external investments, including funding and compliance with legal requirements [9] Investment Procedures - Short-term investment decisions involve pre-selection of investment opportunities by the general manager's office, with financial assessments provided by the finance department [11] - Long-term investment projects require preliminary evaluations and feasibility studies, followed by board approval [12] Financial Management and Auditing - The finance department is responsible for comprehensive financial records of external investments, ensuring compliance with accounting standards [49] - Annual checks of long-term and short-term investments are mandated, along with regular audits of subsidiaries [51][52] Amendments and Effectiveness - The investment management system is subject to amendments as per national laws and regulations, and it becomes effective upon approval by the shareholders' meeting [55]